Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid Agonist Treatment Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

NCT01361568
View directory record Official record
Conditions
Postoperative Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Florence, Alabama • Mobile, Alabama • Montgomery, Alabama + 14 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2Phase 3 Interventional

Tobacco Use in Opioid Agonist Treated Pregnant Women

NCT00497068
View directory record Official record
Conditions
Nicotine Dependence
Interventions
tobacco abstinent contingent, non-contingent, control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Jun 10, 2026, 5:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

NCT05712707
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
New Haven, Connecticut • Eatontown, New Jersey • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Terminated Not applicable Interventional

Distress Tolerance for Benzodiazepine Discontinuation

NCT05250570
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), Relaxation Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Wilkinsburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

NCT06732596
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Embodied conversational agent (ECA), Technical support, Additional ECA messages, Additional incentives
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

NCT00993863
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence

NCT02496403
View directory record Official record
Conditions
Opiate Substitution Treatment
Interventions
Standard Medical Management (SMM)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Benzodiazepine Discontinuation in Opioid Agonist Therapy

NCT04109118
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), BZD discontinuation protocol
Behavioral · Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

Starting Treatment With Agonist Replacement Therapies Follow-up Study

NCT01592461
View directory record Official record
Conditions
Opioid Dependence
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

GLP-1R Agonist Treatment for Opioid Use Disorder

NCT06548490
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nalrexone Facilitated Discontinuation of Buprenorphine

NCT01895036
View directory record Official record
Conditions
Stable Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Study of Computer-Based Treatment for Drug Dependence

NCT01315184
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Recovery Line Support System
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Pilot Test of a Community-based Buprenorphine Treatment Intervention

NCT01761110
View directory record Official record
Conditions
Opioid Dependence, Injection Drug Use
Interventions
Community-based buprenorphine treatment (CBBT) intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Results available

An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment

NCT05051644
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
Steps 2 Change (S2C), Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

NCT00877799
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neurocognitive Effects of Opiate Agonist Treatment

NCT01733693
View directory record Official record
Conditions
Opioid-Related Disorders, HIV, HIV Infections
Interventions
Buprenorphine, Methadone
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 68 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

NCT04470050
View directory record Official record
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Combining Behavioral Treatment With Agonist Maintenance - 1

NCT00000311
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine, methadone
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1999
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

Mobile Platform for Optimizing Wellness and Engagement in Recovery

NCT07178990
View directory record Official record
Conditions
Opioid Agonist Treatment, Alcohol Use Disorder, Opioid Use Disorder
Interventions
Digital Contingency Management Intervention Arm, Digital Wellness Arm
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
19 Years to 63 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy

NCT03022890
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Chronic
Interventions
hatha yoga, health education
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Fall River, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Prolonged Exposure Therapy, Attendance-based monetary incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jun 10, 2026, 5:05 PM EDT